Abstract:Immunotherapy has emerged as a crucial treatment option, particularly for types of cancer that display resistance to conventional therapies. A remarkable breakthrough in this field is the development of chimeric antigen receptor (CAR) T cell therapy. CAR T cells are generated by engineering the T cells of a patient to express receptors that can recognize specific tumor antigens. This groundbreaking approach has demonstrated impressive outcomes in hematologic malignancies, including diffuse large B cell lymphoma, B cell acute lymphoblastic leukemia and multiple myeloma. Despite these significant successes, CAR T cell therapy has encountered challenges in its application against solid tumors, leading to limited success in these cases. Consequently, researchers are actively exploring novel strategies to enhance the efficacy of CAR T cells. The focus lies on augmenting CAR T cell trafficking to tumors while preventing the development of CAR T cell exhaustion and dysfunction. The present review aimed to provide a comprehensive analysis of the achievements and limitations of CAR T cell therapy in the context of cancer treatment. By understanding both the successes and hurdles, further advancements in this promising area of research can be developed. Overall, immunotherapy, particularly CAR T cell therapy, has opened up novel possibilities for cancer treatment, offering hope to patients with previously untreatable malignancies. However, to fully realize its potential, ongoing research and innovative strategies are essential in overcoming the challenges posed by solid tumors and maximizing CAR T cell efficacy in clinical settings.

Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment

Chimeric Antigen Receptor Natural Killer Cells: a Promising Antitumor Immunotherapy

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Fine-Tuning through Generations: Advances in Structure and Production of CAR-T Therapy

Direct in vivo CAR T cell engineering

Challenges and innovations in CAR-T cell therapy: a comprehensive analysis

In vivo gene editing and in situ generation of chimeric antigen receptor cells for next-generation cancer immunotherapy

In vivo engineering chimeric antigen receptor immune cells with emerging nanotechnologies

Biomaterials promote in vivo generation and immunotherapy of CAR-T cells

CAR‐T cell therapy: A breakthrough in traditional cancer treatment strategies (Review)

Investigating chimeric antigen receptor T cell therapy and the potential for cancer immunotherapy (Review)

Recent Progress in Improving the Safety and Efficacy of Chimeric Antigen Receptor T Cell Therapy

CAR products from novel sources: a new avenue for the breakthrough in cancer immunotherapy

CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments

Nanotechnology in Advancing Chimeric Antigen Receptor T Cell Therapy for Cancer Treatment

Current progress in CAR-T cell therapy for tumor treatment

Charting new paradigms for CAR-T cell therapy beyond current Achilles heels

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

Chimeric Antigen Receptor Cell Therapy: Overcoming Obstacles to Battle Cancer

Engineering strategies to overcome the current roadblocks in CAR T cell therapy

Current advances in experimental and computational approaches to enhance CAR T cell manufacturing protocols and improve clinical efficacy